Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-AraG PET imaging for acute GVHD detection
NCT03367962Phase 1Completed
- Sponsor
- CellSight Technologies
- Start
- May 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]fluoro-arabinofuranosyl guanine (3 arms), sponsored by CellSight Technologies. Primary endpoints: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan and Number of Participants Who Developed aGVHD Within 6 Months Post-Scan. Started May 2018; status: completed.
02
Drugs
[18F]fluoro-arabinofuranosyl guanine
Beyond the preview
Go deeper on NCT03367962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367962.